On June 17th, 2024, the US Food and Drug Administration (FDA) approved pembrolizumab (marketed as Keytruda) in combination with chemotherapy drugs cisplatin and paclitaxel, followed by monotherapy, for the treatment of adult patients with primary advanced or recurrent endometrial cancer. According to Merck's press release, Keytruda is currently the first and only anti-PD-1 therapy approved by the FDA for the treatment of primary advanced or recurrent endometrial cancer in adults in combination with chemotherapy, regardless of mismatch repair (MMR) status. Mismatch repair (MMR) refers to one of the clinical commonly used diagnostic markers for endometrial cancer that repairs nucleotide sequences in DNA molecules containing mismatched base pairs.
默沙东K药获批第40个适应证：一线治疗子宫内膜癌
Merck's K drug has been approved for its 40th indication: first-line treatment for endometrial cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.